UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 6, 1999
U.S. Microbics, Inc.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
Colorado 0-14213 84-0990371
- ------------------------- ---------------------- ------------------
(State or other juri- (Commission File Number) (IRS Employer
diction of incorporation) Identification No.)
5922-B Farnsworth Court
Carlsbad, CA 92008
-------------------------------------------------
(address of principal executive offices and zip code)
Registrant's telephone number, including area code:(760)918-1860
Former name or former address, if changed since last report: N/A
<PAGE>
Item 4. Changes in Registrant's Certifying Accountant
Registrant has re-engaged Bradshaw Smith & Co.LLP, as its independent certifying
accountant effective November 22, 1999, dismissing Arthur Andersen LLP its prior
independent certifying accountant, as of the same date. The change in
independent certifying accountant was approved by the Board of Directors of the
Registrant on November 22, 1999.
Arthur Andersen LLP was engaged as the Company's auditors on March 12,
1999. Arthur Andersen LLP has performed tax services for the Registrant during
the interim period of time. The Registrant's dismissal of Arthur Andersen LLP
was part of the Registrant's cost reduction program.
(a) Exhibit 16.1
Letter from Arthur Andersen LLP to the Securities and Exchange Commission
dated, December 6th, 1999.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
U.S. Microbics, Inc.
Date: December 6, 1999 By: /s/ Robert C. Brehm
--------------------------------------
Robert C. Brehm, President and
Chief Executive Officer
By: /s/ Conrad Nagel
--------------------------------------
Conrad Nagel, Chief Financial Officer
EXHIBIT 16.1
Chief Account
Securities and Exchange Commission
Washington D.C. 20549
Board of Directors
U.S. Microbics, Inc.
5922-B Farnsworth court
Carlsbad, CA 92008
Gentlemen:
In accordance with the AICPA's SEC Practice Section requirements we are hereby
reporting the fact that the client-auditor relationship between U. S. Microbics,
Inc. (formerly Global Venture Funding, Inc.) and Arthur Andersen LLP has ceased.
We have read the U. S. Microbics, Inc. statements included under Item 4 of its
form 8-K for December 6, 1999, and we agree with such statements.
Very truly yours,
/s/ Arthur Andersen LLP
Arthur Andersen LLP
San Diego, California
December 6, 1999
